<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1039">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346355</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-TCZ-COVID-19</org_study_id>
    <secondary_id>2020-001386-37</secondary_id>
    <nct_id>NCT04346355</nct_id>
  </id_info>
  <brief_title>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</brief_title>
  <official_title>An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Unità Sanitaria Locale Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Unità Sanitaria Locale Reggio Emilia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study aims at assessing whether early administration of Tocilizumab compared to&#xD;
      late administration of Tocilizumab can reduce the number of patients with COVID-19 pneumonia&#xD;
      who require mechanical ventilation. The clinical study includes patients with recent-onset&#xD;
      COVID-19 pneumonia who require hospital care, but not invasive or semi-invasive mechanical&#xD;
      ventilation procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on interim analysis for futility and given an enrolment rate almost nil&#xD;
  </why_stopped>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Actual">June 6, 2020</completion_date>
  <primary_completion_date type="Actual">June 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation</measure>
    <time_frame>two weeks from participants' allocation to study arm</time_frame>
    <description>Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation documented by the finding of a PaO2 / FiO2 ratio &lt;150mm / Hg confirmed by a second arterial blood gas (ABG) measurement within four hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>Two weeks from participants' allocation to study arm</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tocilizumab toxicity</measure>
    <time_frame>Two weeks from participants' allocation to study arm</time_frame>
    <description>Adverse events (AE) classified according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment</measure>
    <time_frame>Two weeks from participants' allocation to study arm</time_frame>
    <description>Levels of ferritin, lactate dehydrogenase and D-dimer and their correlation with the effectiveness of the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progress of the PaO2 / FiO2 ratio</measure>
    <time_frame>Two weeks from participants' allocation to study arm</time_frame>
    <description>Changes from baseline of the PaO2 / FiO2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the trend over time of the lymphocyte count</measure>
    <time_frame>Two weeks from participants' allocation to study arm</time_frame>
    <description>Changes from baseline of the lymphocyte count</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab within 8 hours from entering the study + standard of care; 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care; In the event of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>In case of aggravation of COVID-19 pneumonia, according to protocol criteria, participants will receive 8 mg/kg IV up to a maximum of 800 mg with repetition of the same dosage after 12 hours</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Standard of care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years&#xD;
&#xD;
          -  Informed consent for participation in the study&#xD;
&#xD;
          -  Real time polymerase chain reaction (PCR) diagnosis of Sars-CoV2 infection&#xD;
&#xD;
          -  Hospitalization due to clinical / instrumental diagnosis (high resolution chest CT&#xD;
             scan or chest x-ray or pulmonary ultrasound)&#xD;
&#xD;
          -  Presence of acute respiratory distress syndrome with arterial partial pressure of&#xD;
             oxygen / fraction of inspired oxygen (PaO2 / FiO2) between 200 and 300 mm/Hg&#xD;
&#xD;
          -  Presence of exaggerated inflammatory response defined by the presence of at least 1 of&#xD;
             the following criteria:&#xD;
&#xD;
          -  At least one body temperature measurement &gt;38° C in the past two days;&#xD;
&#xD;
          -  Serum CRP greater than or equal to 10 mg/dl;&#xD;
&#xD;
          -  CRP increase of at least twice the basal value&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with respiratory distress syndrome with arterial partial pressure of oxygen /&#xD;
             fraction of inspired oxygen (PaO2 / FiO2) &lt;200 mm/Hg or&#xD;
&#xD;
          -  Patients in non-invasive ventilation or&#xD;
&#xD;
          -  Patients in invasive ventilation or presence of shock or presence of concomitant organ&#xD;
             failure that requires admission to the Intensive Care Unit&#xD;
&#xD;
          -  Severe heart and kidney failure&#xD;
&#xD;
          -  Pregnant or breastfeeding patient&#xD;
&#xD;
          -  Patient who, in the opinion of the clinician or by the patient's express will, will&#xD;
             not go to intensive care regardless of the evolution of the lung picture.&#xD;
&#xD;
          -  Known hypersensitivity to TCZ or its excipients&#xD;
&#xD;
          -  Patient being treated with immuno-depressors or anti-rejection drugs&#xD;
&#xD;
          -  Known active infections or other clinical conditions that contraindicate TCZ and&#xD;
             cannot be treated or resolved according to the physician's judgment&#xD;
&#xD;
          -  glutamate-pyruvate transaminase (GPT) or glutamine oxaloacetic transaminase (GOT) &gt; 5&#xD;
             times the upper limit of the norm&#xD;
&#xD;
          -  Neutrophils &lt;500 /mmc&#xD;
&#xD;
          -  Platelets &lt;50.000 /mmc&#xD;
&#xD;
          -  Diverticulitis or intestinal perforation&#xD;
&#xD;
          -  Suspicion of latent tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Salvarani, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massimo Costantini, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ospedale di Guastalla</name>
      <address>
        <city>Guastalla</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Cremona</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Evangelico Internazionale di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sociosanitaria ASL 1 ,Imperia</name>
      <address>
        <city>Imperia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sociosanitaria ASL 5 La Spezia</name>
      <address>
        <city>La Spezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Mantova - Ospedale Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Auxologico Italiano Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Maggiore della Carità&quot; di Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Padova Sud - ULSS 6 Euganea</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Unità Sanitaria Locale di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Ordine Mauriziano di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Bergamo Ovest -Treviglio</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AULSS 2 Marca Trevigiana</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AULSS 3 Serenissima Ospedale &quot;Dell'Angelo&quot;</name>
      <address>
        <city>Venezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Sacro Cuore Don Calabria</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

